QCG
ADMA icon

Quadrant Capital Group’s ADMA Biologics ADMA Stock Holding History

Quadrant Capital Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-187
Closed -$1.69K – 1263
2026
Q1 		$1.69K Sell
187
-526
-74% -$8.3K ﹤0.01% 2531
2025
Q4 		$13K Sell
713
-259
-27% -$4.37K ﹤0.01% 2133
2025
Q3 		$14.3K Sell
972
-15,688
-94% -$269K ﹤0.01% 2058
2025
Q2 		$303K Buy
16,660
+629
+4% +$12.8K 0.01% 1133
2025
Q1 		$318K Buy
16,031
+15,429
+2,563% +$267K 0.01% 1048
2024
Q4 		$10.3K Sell
602
-390
-39% -$7.34K ﹤0.01% 2118
2024
Q3 		$19.8K Buy
+992
New +$15.4K ﹤0.01% 1892
2023
Q4 		– Sell
-867
Closed -$3.1K – 2693
2023
Q3 		$3.1K Hold
867
– – ﹤0.01% 2284
2023
Q2 		$3.2K Hold
867
– – ﹤0.01% 2307
2023
Q1 		$2.87K Buy
+867
New +$3K ﹤0.01% 2357

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Quadrant Capital Group's ADMA Position: Q2 2026 in Review

Quadrant Capital Group sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 187 shares — an estimated $1.69K sold.

Quadrant Capital Group first reported a position in ADMA in Q1 2023 and held it in 10 quarters. The position peaked at $318K in Q1 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Quadrant Capital Group reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 187 ADMA Biologics shares in Q2 2026, an estimated $1.69K.
  • Quadrant Capital Group first reported a position in ADMA Biologics in Q1 2023 and held it in 10 quarters.
  • Quadrant Capital Group's ADMA Biologics position peaked at $318K in Q1 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.